FIGURE 5 from B7-H3–Targeting Chimeric Antigen Receptors Epstein-Barr Virus–specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3–positive Solid Tumors

B7-H3.mCAR T cells exhibit little on-tumor off target toxicity in a syngeneic mouse model. A, Body weight (left), tumor volume measurements (middle), and fold change in tumor volumes (right) of B16F10-hB7H3 tumors after treatment. B, Endpoint murine immune cell counts in blood, bone marrow, spleen, and liver quantified by flow cytometry. Each point on the graph represents a mouse. C, Pathologic evaluation of organs from two B16F10WT-hB7H3 tumor-bearing C57BL/6J mice receiving UT or B7H3.mCAR T cells or left untreated. For A and B, data comprise of 6 mice in each treatment arm. For A, groups were compared using two-way ANOVA with Tukey test for multiple comparisons test. Comparison and P values between untreated versus UT T, untreated versus B7H3.CAR EBVSTs, and UT T versus B7H3.CAR EBVSTs groups is represented in black, blue, and red, respectively. For B, groups were compared using Student unpaired t test. *, P P P P